Watch | USFDA rejects Bharat Biotech's Covaxin for emergency use. Is rejection a setback for company?

The US Food and Drug Administration has refused to give Emergency Use Authorisation (EUA) to Bharat Biotech’s Covaxin. The USFDA has denied it because they don't have enough data yet to grant EUA and has said that the company should pursue a full license process that will take time and involve additional clinical trials. The rejection that puts people into alarm is ''is it a setback, or is there more to it?'' Watch the video.